Latest Breaking News On - Marin submits supplemental applications - Page 1 : vimarsana.com

BioMarin Pharma (BMRN) Announces EMA Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharma (BMRN) Announces EMA Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hank fuchsWorldwide researchEuropean medicines agencyDrug administrationBiomarin pharmaceutical incMarin pharmaceuticalNew drug applicationMarin submits supplemental applicationsYounger children

European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2

European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hank fuchsTraci mccartyEuropean commissionDrug administrationBiomarin pharmaceutical incExchange commissionWorldwide researchHealth authoritiesPrnewswire biomarin pharmaceutical incEuropean medicines agencyEu european union summary of product characteristicsExpand labelTreat childrenAchondroplasia underFavorable resultsGlobal randomized phase